WARRINGTON, Pa., April 28, 2010 (GLOBE NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO) will be hosting a conference call today, Wednesday, April 28, 2010, at 10:00 AM EDT. Management will provide updates on Surfaxin and key pipeline and business initiatives as well as financial results for the first quarter of 2010.

The call in number is 866-332-5218. The international call in number is 706-679-3237. A replay of the conference call will be available two hours after the call's completion and remain available through May 5, 2010. The replay number to hear the conference call is 800-642-1687 or 706-645-9291. The passcode is 71846778.

  About Discovery Labs

Discovery Laboratories, Inc. is a biotechnology company developing surfactant therapies for respiratory diseases.  Surfactants are produced naturally in the lungs and are essential for breathing.  Discovery Labs' novel proprietary KL4 Surfactant Technology produces a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant and is being developed in liquid, aerosol or lyophilized formulations. In addition, Discovery Labs' proprietary capillary aerosolization technology produces a dense aerosol, with a defined particle size that is capable of potentially delivering aerosolized KL4 surfactant to the deep lung without the complications currently associated with liquid surfactant administration. Discovery Labs believes that its proprietary technology platform makes it possible, for the first time, to develop a significant pipeline of surfactant products to address a variety of respiratory diseases for which there frequently are few or no approved therapies. For more information, please visit our website at www.Discoverylabs.com.
CONTACT: Discovery Laboratories, Inc.         John G. Cooper, EVP and Chief Financial Officer         215-488-9300

Discovery Laboratories